LCM
MCID: MNT001
MIFTS: 67

Mantle Cell Lymphoma (LCM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 11 19 58 75 28 5 14 36 16 31 33
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 71
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 71
Malignant Undifferentiated Cell, Non-Burkitt Lymphoma 33
Malignant Small Cell, Noncleaved, Diffuse Lymphoma 33
Diffuse Non-Hodgkin Small Cleaved Cell Lymphoma 33
Diffuse Small Cleaved Cell Malignant Lymphoma 33
Small Cleaved Cell Non-Hodgkin Lymphoma 33
Small Cleaved Cell Malignant Lymphoma 33
Diffuse Small Cleaved-Cell Lymphoma 33
Malignant Lymphomatous Polyposis 33
Small Cell Mantle Cell Lymphoma 33
Lymphoma, Mantle Cell 19
Lymphoma, Mantle-Cell 43
Cleaved Cell Lymphoma 33
Mantle Zone Lymphoma 58
Lymphoma Mantle-Cell 53
Mcl 58
Lcm 58

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-9/1000000 (United States) 1-9/100000 (Europe, France) 58

Age Of Onset:

Adult 58

Age Of Death:

adult 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0050746
MeSH 43 D020522
ICD10 31 C83.1
MESH via Orphanet 44 D020522
ICD10 via Orphanet 32 C83.1
UMLS via Orphanet 72 C0555202
Orphanet 58 ORPHA52416
ICD11 33 1804127841
UMLS 71 C0334634 C0555202

Summaries for Mantle Cell Lymphoma

GARD: 19 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed.

MalaCards based summary: Mantle Cell Lymphoma, also known as malignant lymphoma, lymphocytic, intermediate differentiation, diffuse, is related to lymphoma and burkitt lymphoma. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Cellular responses to stimuli and Prolactin Signaling. The drugs Cyclophosphamide and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, lymph node and t cells, and related phenotypes are lymphadenopathy and b-cell lymphoma

Orphanet: 58 Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma (see this term) affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.

Disease Ontology: 11 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia: 75 Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 599)
# Related Disease Score Top Affiliating Genes
1 lymphoma 33.3 MDM2 IRF4 GAS5 EZH2 CDKN2C CDKN2A
2 burkitt lymphoma 33.1 IRF4 CDKN2A CD44 CCND2 BMI1 BCL6
3 lymphoma, hodgkin, classic 32.8 MDM2 IRF4 BCL6 BCL2 ATM
4 b-cell lymphoma 32.7 MDM2 MALAT1 IRF4 IGH GAS5 EZH2
5 lymphoma, non-hodgkin, familial 32.7 MDM2 IRF4 IGH EZH2 CDKN2C CD44
6 leukemia, chronic lymphocytic 32.6 MTOR MIR16-1 MDM2 IRF4 IGH EZH2
7 follicular lymphoma 32.3 MTOR IRF4 IGH EZH2 CDKN2A CCND1
8 b-cell non-hodgkin lymphoma 32.2 BCL6 ATM
9 diffuse large b-cell lymphoma 32.2 MDM2 IRF4 EZH2 BCL6 BCL2
10 marginal zone b-cell lymphoma 32.1 IRF4 CCND1 BCL6 BCL2
11 leukemia 32.1 GAS5 CDKN2A CCND1 BMI1 BCL2 ATM
12 lymphoma, mucosa-associated lymphoid type 31.9 IRF4 IGH CCND1 BCL6 BCL2
13 hematologic cancer 31.9 MTOR MIR16-1 IRF4 BMI1 BCL2 ATM
14 chronic lymphocytic leukemia/small lymphocytic lymphoma 31.8 CCND1 BCL6 BCL2
15 myeloma, multiple 31.8 MTOR MALAT1 IRF4 GAS5 CDKN2C CD44
16 leukemia, chronic lymphocytic 2 31.7 BCL2 ATM
17 leukemia, acute myeloid 31.7 MTOR MDM2 MALAT1 EZH2 CDKN2A CD44
18 mature b-cell neoplasm 31.7 IRF4 CDKN2A CCND1 BCL6 BCL2
19 peripheral nervous system disease 31.6 MTOR MDM2 EZH2 CDKN2A CD44 CCND1
20 lymphatic system disease 31.6 MIR16-1 IRF4 BCL6 BCL2
21 lymphoplasmacytic lymphoma 31.5 IRF4 CCND1 BCL6 BCL2
22 retinoblastoma 31.5 MDM2 MALAT1 CDKN2C CDKN2A CCNG1 CCND2
23 composite lymphoma 31.5 BCL6 BCL2
24 richter's syndrome 31.5 BCL6 BCL2 ATM
25 adenocarcinoma 31.4 MDM2 MALAT1 CDKN2A CCND1 C11orf65 BCL2
26 t-cell acute lymphoblastic leukemia 31.4 IRF4 GAS5 CCND2 BCL2 ATM
27 leukemia, acute lymphoblastic 31.4 IRF4 IGH CDKN2C CDKN2A CCND2 BCL6
28 lung cancer susceptibility 3 31.3 MALAT1 GAS5 CDKN2A CCND1 BCL2
29 gastrointestinal lymphoma 31.3 CCND1 BCL6 BCL2
30 breast cancer 31.3 MTOR MDM2 MALAT1 GAS5 EZH2 CDKN2A
31 myelodysplastic syndrome 31.3 EZH2 CDKN2C CDKN2A BMI1 BCL2
32 colon lymphoma 31.2 CCND1 BCL6 BCL2
33 nodal marginal zone lymphoma 31.2 IRF4 BCL6 BCL2
34 reticulosarcoma 31.2 IGH BCL6 BCL2
35 squamous cell carcinoma 31.2 MTOR MDM2 MALAT1 CDKN2A CD44 CCND1
36 testicular lymphoma 31.1 IRF4 BCL6 BCL2
37 prostate cancer 31.1 MTOR MIR16-1 MDM2 MALAT1 GAS5 EZH2
38 acute promyelocytic leukemia 31.1 MIR16-1 EZH2 CCND1 BCL6 BCL2
39 colonic benign neoplasm 31.1 CDKN2A CD44 CCND1 C11orf65 BCL2 ATM
40 plasmacytoma 31.0 MTOR IRF4 IGH GAS5 CDKN2A CCND1
41 renal cell carcinoma, nonpapillary 31.0 MTOR MALAT1 GAS5 EZH2 CDKN2A CD44
42 adenoma 31.0 CDKN2A CD44 CCND1 BCL2
43 gastrointestinal stromal tumor 31.0 MTOR MDM2 CDKN2A CCND1 BCL2
44 breast lymphoma 31.0 IRF4 BCL6 BCL2
45 meningioma, familial 31.0 MDM2 CDKN2C CDKN2A CCND1 BCL2
46 gastric lymphoma 31.0 IRF4 BCL6 BCL2
47 pancreatic cancer 30.8 MTOR MIR16-1 MDM2 MALAT1 GAS5 EZH2
48 nervous system disease 30.8 MTOR MIR16-1 MDM2 EZH2 CDKN2A CD44
49 neuroblastoma 30.8 MTOR MDM2 MALAT1 GAS5 EZH2 CDKN2A
50 nasopharyngeal carcinoma 30.8 MDM2 MALAT1 GAS5 EZH2 CDKN2A CD44

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

58 30 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002716
2 b-cell lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012191
3 splenomegaly 58 30 Frequent (33%) Frequent (79-30%)
HP:0001744
4 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
5 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
6 anorexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002039
7 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
8 abnormality of bone marrow cell morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0005561
9 abnormality of the gastrointestinal tract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011024

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ATM BCL6 CCND1 CCNG1 CD44 MDM2

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ATM BCL2 BCL6 BMI1 CCND1 CCND2
2 nervous system MP:0003631 10.31 ATM BCL2 BMI1 CCND1 CCND2 CD44
3 growth/size/body region MP:0005378 10.31 ATM BCL2 BCL6 BMI1 CCND1 CCND2
4 cellular MP:0005384 10.31 ATM BCL2 BCL6 BMI1 CCND1 CCNG1
5 neoplasm MP:0002006 10.29 ATM BCL2 BMI1 CCND1 CCNG1 CD44
6 endocrine/exocrine gland MP:0005379 10.29 ATM BCL2 BCL6 BMI1 CCND1 CCND2
7 immune system MP:0005387 10.21 ATM BCL2 BCL6 BMI1 CCND1 CCND2
8 cardiovascular system MP:0005385 10.18 ATM BCL2 BCL6 BMI1 CCND1 CCND2
9 adipose tissue MP:0005375 10.07 ATM BCL2 BCL6 BMI1 CCND2 IRF4
10 digestive/alimentary MP:0005381 10.06 BCL2 BMI1 CCND1 CCNG1 CD44 CDKN2A
11 reproductive system MP:0005389 10 ATM BCL2 BCL6 BMI1 CCND1 CCND2
12 hematopoietic system MP:0005397 9.97 ATM BCL2 BCL6 BMI1 CCND1 CCND2
13 respiratory system MP:0005388 9.92 BCL6 BMI1 CCND1 CD44 CDKN2A CDKN2C
14 mortality/aging MP:0010768 9.8 ATM BCL2 BCL6 BMI1 CCND1 CCND2
15 integument MP:0010771 9.28 ATM BCL2 BCL6 CCND1 CD44 CDKN2A

Drugs & Therapeutics for Mantle Cell Lymphoma

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 596 6253 6175
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
5
Melphalan Approved Phase 3 148-82-3 4053 460612
6
Carmustine Approved, Investigational Phase 3 154-93-8 2578
7
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Aldesleukin Approved Phase 3 110942-02-4
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Chlorambucil Approved Phase 3 305-03-3 2708
13
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
14
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
18
Epirubicin Approved Phase 3 56420-45-2 41867
19
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
20
Rituximab Approved Phase 3 174722-31-7
21 Antineoplastic Agents, Alkylating Phase 3
22 Antimetabolites Phase 3
23 Antibiotics, Antitubercular Phase 3
24 Immunosuppressive Agents Phase 3
25 Anti-Bacterial Agents Phase 3
26 Alkylating Agents Phase 3
27 Gastrointestinal Agents Phase 3
28 glucocorticoids Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Antiemetics Phase 3
31 Hormones Phase 3
32 Hormone Antagonists Phase 3
33 Anti-Inflammatory Agents Phase 3
34 Mitogens Phase 3
35 interferons Phase 3
36 Interferon-alpha Phase 3
37 Interferon alpha-2 Phase 3
38 Anti-Infective Agents Phase 3
39 Antiviral Agents Phase 3
40
Etoposide phosphate Phase 3 16760419
41 Interleukin-2 Phase 3
42 Anti-HIV Agents Phase 3
43 Anti-Retroviral Agents Phase 3
44 Analgesics, Non-Narcotic Phase 3
45 Analgesics Phase 3
46 Protein Kinase Inhibitors Phase 3
47 Liposomal doxorubicin Phase 3
48 Antineoplastic Agents, Immunological Phase 3
49 Antirheumatic Agents Phase 3
50 Immunologic Factors Phase 3

Interventional clinical trials:

(show top 50) (show all 664)
# Name Status NCT ID Phase Drugs
1 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
2 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus
3 A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma Recruiting NCT04930536 Phase 4 Acalabrutinib capsule
4 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Active, not recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
5 Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Unknown status NCT01449344 Phase 3 Rituximab;High dose Ara-C;Dexamethasone;Bortezomib
6 Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation Unknown status NCT00209209 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Fludarabine;Interferon-alpha;pegylated formula Interferon-alpha 2b
7 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
8 A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma Unknown status NCT02354313 Phase 3 Lenalidomide
9 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
10 Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
11 Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
12 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
13 A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
14 A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
15 Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma Completed NCT00641095 Phase 2, Phase 3 Cyclophosphamide;Fludarabine
16 A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4 Completed NCT00003280 Phase 3
17 An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Investigator's choice
18 A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
19 An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
20 A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
21 Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
22 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
23 Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL Completed NCT00921414 Phase 3 Rituximab
24 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
25 A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101) Completed NCT01597778 Phase 3
26 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
27 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma Recruiting NCT02972840 Phase 3 Acalabrutinib;Bendamustine;Rituximab;Placebo
28 A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) Recruiting NCT04662255 Phase 3 Pirtobrutinib;Ibrutinib;Acalabrutinib;Zanubrutinib
29 A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Recruiting NCT04002297 Phase 3 zanubrutinib;bendamustine;rituximab
30 A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma Recruiting NCT05051891 Phase 3 Orelabrutinib and R-CHOP;R-CHOP
31 Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial Recruiting NCT02858258 Phase 3 R-CHOP/R-DHAP;Ibrutinib (Induction);ASCT conditioning;Ibrutinib (Maintenance)
32 A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Recruiting NCT03267433 Phase 3
33 A Multi-center, Prospective Clinical Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Recruiting NCT05164770 Phase 3 Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX;R-CHOP; R-DA-EPOCH; R-HD MTX
34 Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial Recruiting NCT05020392 Phase 3 BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells;Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
35 A Multi-center and Prospective Clinical Study of Orelabrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Recruiting NCT05097443 Phase 3 Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
36 A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma Active, not recruiting NCT01996865 Phase 3 Lenalidomide;Rituximab
37 Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma Active, not recruiting NCT01865110 Phase 3 R-CHOP;R-CHOP / R-HAD;Rituximab;Lenalidomide
38 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma Active, not recruiting NCT01776840 Phase 3 Bendamustine;Rituximab;Ibrutinib;Placebo
39 Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma Active, not recruiting NCT03112174 Phase 3 Ibrutinib;Venetoclax;Placebo Oral tablet to match Venetoclax
40 Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas Active, not recruiting NCT00877214 Phase 3 Rituximab;Rituximab / observation
41 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 Ibrutinib
42 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting NCT05431179 Phase 3 Zilovertamab;Ibrutinib;Placebo
43 A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician's Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting NCT05564052 Phase 2, Phase 3 Ibrutinib;Lenalidomide;Rituximab;Bortezomib
44 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma Terminated NCT01021423 Phase 3 Lenalidomide
45 UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies Terminated NCT00714259 Phase 2, Phase 3 Fludarabine
46 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma Terminated NCT02793583 Phase 2, Phase 3 Umbralisib
47 A Phase 3, Randomized, Double-Blind Study Comparing Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab (BR), With Placebo and BR for the Treatment of Newly Diagnosed Mantle Cell Lymphoma Withdrawn NCT04849715 Phase 3 parsaclisib;rituximab;bendamustine;Placebo
48 A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) Withdrawn NCT02735876 Phase 3 acalabrutinib;ibrutinib;rituximab
49 A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy Unknown status NCT02652910 Phase 1, Phase 2 CD19.CAR-T cells
50 A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma Unknown status NCT02685670 Phase 1, Phase 2 Fludarabine;Cyclophosphamide

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ibrutinib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 28

Anatomical Context for Mantle Cell Lymphoma

Organs/tissues related to Mantle Cell Lymphoma:

MalaCards : B Cells, Lymph Node, T Cells, Bone Marrow, Bone, Nk Cells, Myeloid

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 5615)
# Title Authors PMID Year
1
Mantle cell lymphoma is characterized by inactivation of the ATM gene. 62 5
10706620 2000
2
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. 62 46
18483394 2008
3
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 53 62
20062012 2010
4
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. 53 62
18606985 2008
5
Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. 53 62
17488676 2007
6
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. 53 62
17145584 2006
7
Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. 53 62
16956411 2006
8
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. 53 62
16448697 2006
9
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. 53 62
11389032 2001
10
Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. 53 62
9846986 1998
11
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. 53 62
9209645 1997
12
Chronic lymphoproliferative disorders. 53 62
9090492 1997
13
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. 53 62
8695815 1996
14
Mantle-cell lymphoma: classification and therapeutic implications. 53 62
9010577 1996
15
Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. 53 62
7772515 1995
16
Histogenesis and pathogenesis of follicular small cleaved cell lymphoma (FSCCL), diffuse small cleaved cell lymphoma (DSCCL) and intermediate lymphocytic lymphoma/lymphocytic lymphoma of intermediate differentiation (ILL/IDL). 53 62
7642169 1994
17
The presence of bcl-1 and bcl-2 gene rearrangements in diffuse small cleaved-cell lymphoma. A disease with diverse molecular and immunophenotypic findings. 53 62
7981893 1994
18
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. 53 62
8204893 1994
19
PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. 53 62
7918073 1994
20
Identification of genetic lesions associated with diffuse large-cell lymphoma. 53 62
8172819 1994
21
bcl-2 gene expression in hematopoietic cell differentiation. 53 62
1638028 1992
22
Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma. 53 62
1643614 1992
23
Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. 62
36029002 2022
24
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. 62
35466438 2022
25
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. 62
35639332 2022
26
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. 62
36227519 2022
27
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. 62
35596920 2022
28
IBCL-429 Prevalence of B-Cell Chronic Lymphoproliferative Disorders at a Large Tertiary Care Center in India. 62
36164116 2022
29
Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. 62
36252483 2022
30
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape. 62
36266281 2022
31
Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. 62
36226498 2022
32
IBCL-349 Veterans With Agent Orange Exposure Have a Shorter Latency From Exposure to Diagnosis of Indolent B-Cell Lymphoid Malignancies Compared to Unexposed Veterans. 62
36164109 2022
33
CXCR4-targeted theranostics in oncology. 62
35674738 2022
34
MCL-319 LP-284 - A Highly Potent Small Molecule Targeting Mantle Cell Lymphoma. 62
36164123 2022
35
IBCL-081 MAGNIFY Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis. 62
36164099 2022
36
Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. 62
35859066 2022
37
Circulating Tumor DNA in Lymphoma. 62
36214943 2022
38
CT-321 Uncommon Viral Infections in Patients Treated With CAR-T Cell Therapy: Concurrent Adenovirus and BK Virus Infection in a Mantle Cell Lymphoma Patient Within 30 Days After Receiving Brexucabtagene Autoleucel. 62
36164215 2022
39
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. 62
35963941 2022
40
[scRNA-sequencing uncovers metabolism and CD52 as new targets in ibrutinib-surviving mantle cell lymphoma cells]. 62
36222922 2022
41
[18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma. 62
36223113 2022
42
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. 62
35894253 2022
43
Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma. 62
36225622 2022
44
'Primary CNS Blastoid Variant of Mantle Cell Lymphoma: A Unique Case'. 62
36258737 2022
45
Prognostic value and computer image analysis of p53 in mantle cell lymphoma. 62
35918462 2022
46
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. 62
35984628 2022
47
Mantle cell lymphoma in human immunodeficiency virus-infected patients. 62
36223890 2022
48
Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy? 62
36227407 2022
49
EXABS-204-MCL The Role of Targeted Therapies in Frontline Treatment of Mantle Cell Lymphoma. 62
36164250 2022
50
EXABS-206-MCL Emerging Treatment Options for Mantle Cell Lymphoma. 62
36164252 2022

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ATM NM_000051.4(ATM):c.4081C>T (p.Gln1361Ter) SNV Pathogenic
3041 rs121434222 GRCh37: 11:108158414-108158414
GRCh38: 11:108287687-108287687
2 ATM, C11orf65 NM_000051.4(ATM):c.7268A>G (p.Glu2423Gly) SNV Pathogenic
3039 rs121434221 GRCh37: 11:108199926-108199926
GRCh38: 11:108329199-108329199
3 ATM, C11orf65 NM_000051.4(ATM):c.7251_7253dup (p.Lys2418_Arg2419insLys) DUP Pathogenic
3040 rs796051857 GRCh37: 11:108199908-108199909
GRCh38: 11:108329181-108329182

Copy number variations for Mantle Cell Lymphoma from CNVD:

6 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT1 Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39A Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss POGLUT2 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss TMCO3 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss DCUN1D2 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP3 Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number MIR17HG Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation TP53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GABBR2 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 MTOR MDM2 EZH2 CDKN2C CDKN2A BMI1
2
Show member pathways
13.44 ATM BCL2 CCND1 CCND2 CDKN2A CDKN2C
3
Show member pathways
12.92 MTOR MDM2 CDKN2A CCNG1 BCL6 ATM
4
Show member pathways
12.91 MTOR MDM2 CCND2 CCND1 BCL2
5
Show member pathways
12.79 MIR16-1 EZH2 CD44 CCND2 CCND1
6
Show member pathways
12.68 MDM2 EZH2 CDKN2C CDKN2A BMI1 ATM
7
Show member pathways
12.67 MTOR MDM2 CDKN2A CCND1 BCL2
8
Show member pathways
12.47 CDKN2C CDKN2A CCND2 CCND1
9
Show member pathways
12.45 CDKN2C CDKN2A CCND2 CCND1
10
Show member pathways
12.43 ATM CCND1 MDM2 MTOR
11
Show member pathways
12.41 MTOR MDM2 BCL2 ATM
12 12.41 MDM2 CDKN2C CDKN2A CCND2 CCND1 ATM
13
Show member pathways
12.23 CCND1 CCND2 IGH MDM2 MTOR
14 12.21 IRF4 CDKN2C CDKN2A CCND1 BCL6
15
Show member pathways
12.17 MDM2 CCND1 BCL2 ATM
16
Show member pathways
12.17 MTOR MDM2 CCND2 CCND1 BCL2
17
Show member pathways
12.11 MDM2 CDKN2C CDKN2A CCND2 CCND1 ATM
18 12.1 MTOR MDM2 CCND1 BCL2 ATM
19
Show member pathways
12.04 CDKN2C CDKN2A CCND2 CCND1 ATM
20
Show member pathways
12.02 ATM CCND1 CCND2 CCNG1 MDM2
21 12.01 MDM2 CCNG1 BCL6 BCL2
22 11.94 CDKN2A CD44 CCND1
23 11.93 MTOR MDM2 EZH2 CDKN2A CD44 CCND2
24 11.92 IRF4 CCND1 BCL6 BCL2
25 11.88 MTOR CCND1 BCL6 BCL2
26
Show member pathways
11.87 MDM2 CDKN2A ATM
27
Show member pathways
11.84 MTOR CD44 CCND1
28 11.77 MDM2 BCL6 ATM
29 11.77 CDKN2A CCND1 BCL2
30 11.76 EZH2 CD44 BMI1
31 11.72 CCND1 CDKN2A MTOR
32 11.72 BCL6 EZH2 MTOR
33 11.71 CDKN2A CCND2 CCND1
34 11.68 MTOR CCND1 ATM
35 11.68 MDM2 CDKN2A BCL2 ATM
36 11.67 MIR16-1 CCND1 ATM
37 11.66 CDKN2C CDKN2A ATM
38 11.65 MTOR MDM2 CDKN2A CD44 BMI1 BCL2
39 11.62 CDKN2C CDKN2A CCND2 CCND1
40 11.61 MTOR IRF4 BCL6
41
Show member pathways
11.59 ATM CCNG1 CDKN2A MDM2 MTOR
42 11.51 MDM2 CDKN2A CCNG1 ATM
43 11.48 MDM2 CDKN2A ATM
44 11.44 MDM2 CCND2 CCND1 BCL6 BCL2 ATM
45 11.42 CCND2 CCND1 BCL2
46 11.4 MDM2 CDKN2A CCND1
47 11.38 MDM2 CCND2 CCND1 ATM
48 11.37 ATM BCL2 MDM2
49 11.29 MDM2 CDKN2C CDKN2A
50 11.21 CCNG1 CCND2 CCND1 ATM

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.1 CCNG1 CCND2 CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.13 MIR16-1 CDKN2A BCL6 BCL2 ATM
2 cell cycle GO:0007049 10.1 ATM CCND1 CCND2 CCNG1 CDKN2A CDKN2C
3 negative regulation of cell growth GO:0030308 10.03 CDKN2C CDKN2A BCL6 BCL2
4 negative regulation of apoptotic process GO:0043066 10.03 MTOR MDM2 CD44 CCNG1 CCND2 BCL6
5 cellular response to hypoxia GO:0071456 10 MTOR MDM2 MALAT1 BCL2
6 positive regulation of B cell proliferation GO:0030890 9.95 BMI1 BCL6 BCL2
7 regulation of G1/S transition of mitotic cell cycle GO:2000045 9.93 CDKN2C CDKN2A CCND1
8 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.91 MIR16-1 EZH2 BCL2
9 mitotic cell cycle phase transition GO:0044772 9.8 CCNG1 CCND2 CCND1
10 G1/S transition of mitotic cell cycle GO:0000082 9.76 BCL2 CCND1 CCND2 EZH2
11 regulation of cell cycle GO:0051726 9.65 MDM2 CDKN2A CCNG1 CCND2 CCND1 BCL2
12 positive regulation of response to stimulus GO:0048584 9.55 MTOR ATM
13 response to stress GO:0006950 9.4 ATM MTOR
14 regulation of nucleobase-containing compound metabolic process GO:0019219 9.37 MTOR ATM
15 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.32 CDKN2C CDKN2A CCNG1 CCND2 CCND1

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.1 CCNG1 CCND2 CCND1

Sources for Mantle Cell Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....